|
 Delivering Unmatched Value
Businesses can only be truly successful if they are passionate about the work they do and are able to do it better than anyone else. At ViraCor, we are passionate about making a difference in our patients’ lives and our molecular diagnostic testing is unparalleled.”
- John Martin, President
ViraCor Laboratories is a clinical molecular diagnostic and research laboratory dedicated to detecting and monitoring infections in the immunocompromised patient population, which includes, but is not limited to, transplant patients, autoimmune disease patients, preterm infants, HIV patients, and cancer patients. ViraCor was the first, and remains the only, molecular diagnostic testing laboratory in the United States devoted to serving immunocompromised patients. Our expertise is in infectious diseases critical to immunocompromised and transplant patients over their lifetime, including viruses, protozoa, and fungi. In addition, we extensively study the immune function of patients at risk for serious infection from these pathogens. Our commitment to the immunocompromised patient population permeates all aspects of our business and has set a new standard for the role of laboratory diagnostics in the management of these highly specialized and diverse patients.
ViraCor set the benchmark for the diagnostic industry by turning patient results around in 24 hours or less. Traditionally, lab results had a turnaround time of anywhere from 3 days to several weeks, depending upon the method. We know that fast, clinically meaningful results are critical to patient outcomes, especially immunocompromised patients. From our company’s inception, we have delivered results with superior accuracy as fast as possible, which is often in far less time than our 24 hour guarantee.
Using cutting-edge technology, such as real-time PCR, ViraCor is able to amplify the smallest amounts of an organism for detection. This enables positive identification of a specific pathogen and its quantity in a sample, giving healthcare professionals information to gauge the magnitude of the infection and monitor a patient’s response to treatment. ViraCor developed the first commercially available real-time quantitative PCR test for adenovirus, BK virus and JC virus. Our research laboratory is continually experiencing breakthroughs that will lead to new and novel assays.
Since ViraCor began in 2000, we have become trusted partners of transplant hospitals nationwide, including 60% of all pediatric transplant hospitals. Collaborative partnerships with prestigious academic institutions have led to many impactful studies, serving to progress scientific knowledge of infectious diseases in transplant patients and continual improvement in available diagnostics. We leveraged our relationships in the field to form a Clinical Advisory Team composed of domain experts, a resource that has become a key part of our decision-making process at ViraCor. We seek their professional opinions on subjects ranging from demand for new assays in the immunocompromised patient community to technical aspects of how best to report results. Insights from our Clinical Advisory Team assist us in meeting the needs of immunocompromised patients in the most effective manner possible.
Our entrepreneurial spirit has fueled ViraCor’s growth. We recently expanded into the pharmaceutical clinical trial testing market, creating global opportunities to share our innovative approach to diagnostics. Our research investment has proven successful with the development of much needed assays to diagnose patients with previously undetectable pathogens. ViraCor’s commitment to advance diagnostic practices has created a future bright with opportunities to improve patient care and continue to create unmatched value for our clients.
|
